For treatment of pyelonephritis, which option should be used until culture results are available?

• A. Cefpodoxime or fluoroquinolones until culture results
• B. Amoxicillin/clavulanate
• C. Doxycycline
• D. Clindamycin

Answer: (A)

In pyelonephritis, start empiric therapy with an antibiotic that reliably covers the common urinary pathogens (primarily Enterobacteriaceae like E. coli) and reaches good concentrations in the kidney and urine. Cefpodoxime, a third-generation cephalosporin given orally, provides solid coverage against typical uropathogens and has dependable urinary penetration. Fluoroquinolones, such as ciprofloxacin or levofloxacin, also achieve high levels in urine and renal tissue and are effective for pyelonephritis. These options are appropriate while awaiting culture and susceptibility results because they offer broad, reliable activity against the organisms most likely to cause the infection, with the ability to switch to a more targeted therapy once the results are back.

Amoxicillin/clavulanate, while useful for some infections, has growing resistance among urinary pathogens and may not provide reliable coverage for pyelonephritis. Doxycycline lacks consistent activity against the common Gram-negative uropathogens. Clindamycin does not cover most Gram-negative rods responsible for pyelonephritis, making it unsuitable for empiric therapy in this scenario. You’d de-escalate or change therapy based on culture results to a drug with confirmed susceptibility.